Keywords: duska, files, ph, iii, atpace, protocol, fda

Duska files Ph III ATPace protocol with FDA

Article | 04 August 2008

Print This

California, USA-headquartered Duska Therapeutics has submitted for comment a synopsis of a proposed Phase III clinical study for its lead ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in